|
| 2009～2013年浙江省11家医院肺癌患者升血小板药物利用调查 |
| Survey and Analysis of Platelet Elevating Drugs Used for Lung Cancer Patients in 11 Hospitals of Zhejiang Province During 2009-2013 |
| |
| DOI： |
| 中文关键词: 升血小板药物 浙江省 肺癌 用药金额 用药频度 |
| 英文关键词:Platelet elevating drugs Zhejiang province Lung cancer Daily costs DDDs |
| 基金项目: |
|
| 摘要点击次数: 874 |
| 全文下载次数: 1046 |
| 中文摘要: |
| 摘 要 目的:了解浙江省肺癌患者升血小板药物应用现状，为促进合理用药提供参考。方法：以肿瘤患者升血小板药物指南推荐的重组人白细胞介素-11（IL-11）和重组人血小板生成素(rhTPO)作为研究对象，抽取浙江省11家医院2009～2013年全院肺癌患者每年40d的用药医嘱，回顾性分析用药金额、用药频度（DDDs）、限定日费用（DDC）、科室分布及各药物所占比例。结果：2009～2012年肺癌患者使用升血小板药物的用药金额呈逐年上升趋势，且升血小板药物在所有药物中所占比例逐年上升，至2013年略有下降。药物使用的DDDs与DDC值总体呈上升趋势。使用金额比例排名前3位的分别为放疗科（38.94%）、肿瘤科(34.43%)、肿瘤内科（10.04%）。2010~2013年升血小板药物使用金额以日均费用较低的IL 11所占比例较高。结论：2009~2013年浙江地区肺癌患者升血小板药物的使用情况基本合理，使用趋势偏向价格适中的药物，符合药物经济学原则。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate and analysis the applicational situation of platelet elevating drugs used by patients with lung cancer in Zhejiang province, in order to provide reference to promote rational drug use. Methods:According to The medication guidance of chemotherapy induced thrombocytopenia, recombinant human Interlukin-11 (IL-11) and recombinant human thrombopoietin(TPO) were selected as the objects of our study. Data were extracted from patients’ prescriptions of 11 hospital of Zhejiang province during 2009 2013 with 40 days of each year. Then the sum of drug consume, the frequency of utilization(DDDs), the defined daily cost (DDC), the distribution of departments and the proportion of each drugs were analyzed. Results:The overall cost of platelet elevating drugs used by lung cancer patients increased year by year during 2009 2012, and their proportion within all drugs also increased every year, but slightly decreased in 2013. Generally the DDDs and DDC value of this two drugs showed an upward trend year by year. The top 3 rank using this two drugs in lung cancer patients were department of radiotherapy (38.94%), department of oncology (34.43%) and department of internal medicine of oncology (10.04%). From 2010 to 2013, the mainly using of elevating platelet drug was IL 11, which has a lower DDC value than the other one. Conclusion:The application situation of platelet elevating drugs used by patients with lung cancer was reasonable in Zhejiang province during 2009 2013, and the utilization trend to drugs with moderate price which conformed to the pharmacoeconomics. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
